Under an expanded agreement with J&J, Catalent Biologics will increase manufacturing capacity at its Anagni, Italy, site to accommodate the large-scale commercial supply of Janssen’s COVID-19 vaccine.
Catalent announced on March 17, 2021 that it has expanded its partnership with Janssen Pharmaceutica NV and Janssen Pharmaceuticals, two of the Janssen Pharmaceutical Companies of Johnson & Johnson, under which Catalent Biologics will increase manufacturing capacity at its Anagni, Italy, site to accommodate the large-scale commercial supply of Janssen’s COVID-19 vaccine.
Under the terms of the expanded agreement, which also includes vial-filling, inspection, labeling, and packaging services, Catalent will fast-track the qualification and scale-up of an additional high-speed vial-filling line that is set to be operational in the fourth quarter of 2021 to support vaccine production through late 2022, Catalent said in a company press release.
“We are pleased to expand our partnership with Janssen to support demand of its COVID-19 vaccine in Europe,” said Mario Gargiulo, president, Catalent Biologics, Europe, in the press release. “Our global network of state-of-the-art biologics facilities, combined with our deep expertise in manufacturing scale-up and commercial launch, is well-suited to help provide a solution to this public health crisis.”
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.